This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Al-Ashmawy AAK , Ragab FA , Elokely KM , Anwar MM , Perez-Leal O , Rico MC , Gordon J , Bichenkov E , Mateo G , Kassem EMM , Hegazy GH , Abou-Gharbia M , Childers W
Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kalpha/mTOR inhibitors
Bioorg Med Chem Lett. 2017 Jul 15;27(14) :3117-3122
PMID: 28571824 URL: https://www.ncbi.nlm.nih.gov/pubmed/28571824
AbstractPI3Kalpha/mTOR ATP-competitive inhibitors are considered as one of the promising molecularly targeted cancer therapeutics. Based on lead compound A from the literature, two similar series of 2-substituted-4-morpholino-pyrido[3,2-d]pyrimidine and pyrido[2,3-d]pyrimidine analogs were designed and synthesized as PI3Kalpha/mTOR dual inhibitors. Interestingly, most of the series gave excellent inhibition for both enzymes with IC50 values ranging from single to double digit nM. Unlike many PI3Kalpha/mTOR dual inhibitors, our compounds displayed selectivity for PI3Kalpha. Based on its potent enzyme inhibitory activity, selectivity for PI3Kalpha and good therapeutic index in 2D cell culture viability assays, compound 4h was chosen to be evaluated in 3D culture for its IC50 against MCF7 breast cancer cells as well as for docking studies with both enzymes.
Notes1464-3405 Al-Ashmawy, Aisha A K Ragab, Fatma A Elokely, Khaled M Anwar, Manal M Perez-Leal, Oscar Rico, Mario C Gordon, John Bichenkov, Eugeney Mateo, George Kassem, Emad M M Hegazy, Gehan H Abou-Gharbia, Magid Childers, Wayne Journal Article England Bioorg Med Chem Lett. 2017 Jul 15;27(14):3117-3122. doi: 10.1016/j.bmcl.2017.05.044. Epub 2017 May 15.